<DOC>
	<DOCNO>NCT00175864</DOCNO>
	<brief_summary>This safety efficacy study add therapy seletracetam patient experience refractory epilepsy .</brief_summary>
	<brief_title>Open Label Study ( Everyone Who Participates Receives Drug ) Further Determine How Safe Effective Oral Treatment Seletracetam Patients With Refractory Epilepsy .</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<criteria>An IRB/IEC approve write informed consent form sign dated Male/Female patient age 18 ( 16 year permit law ) 65 . Minimum body weight 40 kg . Patients confirm diagnosis refractory epilepsy ≥ 6 month . Patients must receive 1 3 concomitant AEDs . Female patient without childbearing potential ( 2 year postmenopausal surgical sterilization ) eligible . Female patient childbearing potential eligible use medically accept nonhormonal contraceptive method . Seizures occur cluster ( seizure occur either frequently indistinctly separate reliably count ) . Status epilepticus within 3 month Visit 1 . History nonepileptic seizure . Patients vigabatrin . Patients felbamate , unless treatment continuous ≥ 18 month . Use benzodiazepine ( indication ) take high frequency average week , unless count one concomitant AEDs . Ongoing psychiatric disease mild control disorder . Patients clinically significant organ dysfunction . Known allergic reaction intolerance pyrrolidine derivative and/or excipients . Pregnant lactating woman . Any woman childbearing potential use medically accept , nonhormonal method birth control .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Partial Onset , Primary Generalized Seizures , Seletracetam</keyword>
</DOC>